Pfizer CentreOne Adds Highly Potent Solid Oral Dose to its Service Portfolio

Pfizer CentreOne has grown its service portfolio to include contract manufacturing of highly potent solid oral dose medicines. The service will be provided at the Pfizer Newbridge, Ireland, facility, which is now part of Pfizer CentreOne’s contract manufacturing network. The Pfizer site, near Dublin, has a long history of contract manufacturing and packaging highly potent solid oral drugs with advanced technologies.

“We are pleased to add the Newbridge facility to our network to offer a wider array of services and state-of-the-art containment, manufacturing and packaging technologies to our partners around the globe,” said Peter Stevenson, Vice President and General Manager, Pfizer CentreOne.

Currently approved to supply pharmaceuticals in more than 100 markets, the site’s regulatory approvals include the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Agência Nacional de Vigilância Sanitária (ANVISA) (Brazil) and Pharmaceuticals and Medical Devices Agency (PDMA) (Japan).

  • <<
  • >>

Join the Discussion